一种针对HER2的新型纳米剂,自组装自affibody-epothilone B联合体,用于癌症治疗
Xuelin Xia1, Xiaoyuan Yang1, Wenhui Gao1
1School of Chemistry and Chemical Engineering, Frontiers Science Center for Transformative Molecules, Shanghai Jiao Tong University, Shanghai, 200240, People's Republic of China.
Journal of nanobiotechnology
|August 21, 2024
概括
这项研究介绍了一种用于癌症治疗的新型向纳米剂. 附体药物合纳米剂 (Z-E ADCN) 有效地将Epothilone B传递给HER2阳性瘤,提高疗效并减少副作用.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 在瘤学瘤学.
背景情况:
- 乙乙烯 (Epo B) 作为抗瘤剂具有前景,但具有较差的选择性和狭窄的治疗窗口.
- 亲体蛋白提供精确的向癌细胞过度表达特定受体.
- 反应性氧物种 (ROS) 与瘤微环境有关.
研究的目的:
- 通过将Epothilone B与Affibody结合,开发一种针对性纳米剂,以改善癌症治疗.
- 为了创建一种药物递送系统,以响应瘤特异性条件 (如高ROS水平) 释放Epothilone B.
- 在HER2阳性癌症模型中评估新型纳米剂的疗效和安全性.
主要方法:
- 一个核心外纳米剂 (Z-E ADCN) 的自组装,使用一个 thioketal (tk) 链接器将 ZHER2:342 Affibody 与 Epothilone B. 结合起来.
- 在Affibody冠状体内封装Epothilone B以形成纳米剂.
- 在HER2阳性瘤模型中对Z-E ADCN向,药物释放和抗癌疗效的体外和体内评估.
主要成果:
- 在HER2阳性瘤中,Z-E ADCN表现出增强的向和积累.
- 纳米剂是通过HER2受体介导的内细胞结合体内化.
- 乙乙释放是由癌细胞内的高ROS水平引发的,导致显著的瘤生长抑制.
- 由于向药物输送,在正常器官中观察到减少副作用.
结论:
- 开发的ZHER2:342-Epo B附体-药物结合纳米剂 (Z-E ADCN) 为向癌症治疗提供了一个有前途的战略.
- 对ROS敏感的链接器和Affibody向增强了药物输送,并减少了全身毒性.
- 在HER2阳性瘤模型中,Z-E ADCN表现出强大的抗癌疗效,突出了其临床潜力.
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:27Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K